EUCTR2013-004456-38-GB进行中（未招募）不适用
A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy
Xention Limited0 个研究点开始时间: 2013年11月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent.
- •2. Patients of either sex, aged 18 years and older with paroxysmal AF confirmed within 6 months prior to Screening and Washout.
- •3. Dual chamber pacemaker with appropriate arrhythmia diagnostics for at least 1 month prior to Screening and Washout
- •4. Able to tolerate withdrawal of Class I and III antiarrhythmic drugs (such as Flecainide, Sotalol, Dronedarone or Amiodarone).
- •5. Able to tolerate pacemaker antiarrhythmic algorithms being turned off at Screening and Washout, if applicable.
- •6. Evidence of AF burden 1% and 50% prior to Visit 2 (Day 1).
- •7. Anticoagulated in accordance with European Society of Cardiology (ESC) Guidelines.
- •8. Women must be of non child bearing potential. Non-child bearing potential is defined as amenorrheic for at least 2 years AND have serum follicle stimulating hormone [FSH] level of at least 30 IU/L) or have undergone a hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable). If partners of male patients are of childbearing potential, the patient must be willing to use contraception (e.g. condoms).In addition, their female partner must also be using contraception (e.g. hormonal, intra-uterine device etc). This double contraception must be used from the first dose of study drug until at least 90 days after the last dose of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Cardiac ablation procedure within 3 months prior to Screening and Washout.
- •2. QTc interval >450 ms on Day 1.
- •3. History of clinically significant ventricular arrhythmia.
- •4. History of long QT syndrome.
- •5. Concomitant treatment with any Class I or III anti-arrhythmic drugs (such as Flecainide, Sotalol, Dronedarone or Amiodarone) on Day 1. Treatment with oral Amiodarone must be stopped 6 weeks prior to Study Day 1. In the case of intravenous Amiodarone, a cumulative dose of >5g in the period between Screening and Washout and Day 1 is unacceptable. In the case of all other Class I or III anti-arrhythmic drugs, they must be stopped for at least 2 weeks prior to Day 1.
- •6. Heart failure with symptoms consistent with New York Heart Association [NYHA] classes III-IV. Patients with NYHA I-II heart failure can be enrolled if there have beenno hospital admissions for exacerbations of heart failure within 6 months prior to screening
- •7. Myocardial infarction within 3 months of Screening and Washout; coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) within 6 months of Screening and Washout, or unstable angina within 3 months of the Screening and Washout.
- •8. Transient ischaemic attack (TIA) or stroke within 3 months of Screening and Washout.
- •9. Body mass index (BMI) >36 kg/m2 at Screening and Washout.
- •10. Patient is unable or unwilling to co-operate with the study procedures.
- •11. Participation in any other clinical trials within 30 days prior to Screening and Washout.
- •12. Substance or alcohol abuse (as defined by Diagnostic and Statistical Manual of Mental Disorders Forth Edition) within 6 months of Screening and Washout.
- •13. The following laboratory abnormalities at Screening and Washout, with the provision that repeat samples may be considered for this criterion at the discretion of the Sponsor:
- •a. Serum potassium of <3.5mmol/L or >5.5mmol/L
- •b. Serum magnesium <0.7mmol/L
- •c. Calculated creatinine clearance (using the Cockcroft-Gault method) of <50ml/min
- •d. Serum alanine transaminase (ALT), aspartate transaminase (AST) or gamma-glutamyl transpeptidase (GGT) greater than twice the upper limit of normal (ULN).
- •e. Total serum bilirubin >1.5x ULN.
- •f. Serum haemaglobin <9g/L (women) or 11g/L (men)
- •14. Taking medication which is a CYP3A4 substrate with a narrow therapeutic window (see section 9.8.3)
- •15. Evidence of any other clinically significant disease or condition which in the opinion of the Investigator would preclude the patient's participation in this study
研究者
相似试验
招募中
1 期
Sleep disturbances in subjects with asthma and rhinitis”ACTRN12606000095561The Woolcock Institute30
已完成
不适用
Blackcurrant juice study: a study to investigate the biokinetics and effects of a blackcurrant juice on endothelial functioAbsorption of phytochemicals and effects on endothelial functionNutritional, Metabolic, EndocrineISRCTN26166772GlaxoSmithKline Nutritional Healthcare (UK)20
进行中（未招募）
不适用
A double blind, randomized, placebo-controlled, cross-over study to evaluate the effects of Levetiracetam on membrane excitability properties of afferent myelinated and unmyelinated fibers and change in neuropathic pain in patients with painful traumatic nerve injury.europathic pain due to a traumatic nerve lesionEUCTR2004-002114-11-ESInfociencia Clinical Research
已完成
2 期
A double blind, randomized, placebo controlled, cross-over study to validate the predictive power of the demarcation formula for Lybrido and Lybridos efficacy in women with female sexual interest/arousal disorder, in the domestic situation.problems with sexual functioning10040480sexual dysfunctionNL-OMON40620Companion Diagnostics BV150
尚未招募
4 期
A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers.Cystic FibrosisACTRN12618000283279Mater Misericordiae Ltd20